Recent studies reveal stark inequalities in access to popular new weight-loss medications like Ozempic and Wegovy, highlighting persistent racial and socioeconomic health disparities in the United States. While these drugs have gained widespread attention, their availability remains limited in low-income neighborhoods and communities of color.
Research shows that Black and Hispanic patients, who are more likely to suffer from obesity and Type 2 diabetes, are less likely to be prescribed these medications. A University of Florida study found that Black diabetes patients in regions with high use of GLP-1 weight-loss drugs are half as likely to have access compared to their White counterparts. Another analysis by Komodo Health reported that 65% of patients prescribed these drugs were White, despite White individuals comprising only 59% of the U.S. population.
Factors contributing to this disparity include lack of insurance coverage, absence of regular healthcare, low income, and limited education. Many low-income areas face additional challenges such as food deserts and limited access to medical care.
Atlanta City Council member Antonio Lewis, representing a district with significant health challenges, emphasizes the potential impact of these drugs: “If the federal government would invest only a fraction of what was committed to delivering coronavirus shots and apply that to weight-loss medication, we could save so many lives.”
While some community initiatives focus on promoting healthy living habits, the lack of basic medical coverage remains a significant barrier for many. As the debate over these medications continues, the unequal access underscores broader issues of healthcare disparities in America.
See “Weight-loss drugs are a hot commodity. But not in low-income neighborhoods.” (August 19, 2024)
